Swedish company Salipro Biotech has entered into a multi-target antibody research agreement with biotech company Icosagen.
The agreement leverages Salipro鈥檚 proprietary platform technology for membrane proteins to identify drugs that target specific G protein-coupled receptors (GPCRs) and solute carrier (SLC) transporters, as per a 10 October announcement. These membrane proteins play a role in different areas such as oncology and autoimmune diseases.
Estonian company Icosagen has , with expertise in protein production and analytics, which contributes to the drug development of monoclonal antibodies.
Icosagen will utilise its QMCF technology to advance the project, based on the . The company鈥檚 QMCF technology is based on a proprietary mammalian expression system for producing recombinant proteins.
Monoclonal antibodies have been identified by GlobalData as a key innovation area for cancer therapy, with Johnson & Johnson being the leading patent filer in this category.
Monoclonal antibodies are high-grossing drugs for the business. The company鈥檚 monoclonal antibody Stelara (ustekinumab) has generated $5.2bn in global sales in H1 2023, as per the company鈥檚 Q2 financials.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataJohnson & Jonhson鈥檚 other monoclonal antibodies such as Darzalex (daratumumab), Simponi (golimumab) and Tremfya (guselkumab) have generated $4.6bn, $1bn and $1.3bn, respectively, in global sales in the same period.
GlobalData is the parent company of 色界吧 Technology.
Salipro has multiple partnerships to develop drugs that target membrane proteins and ion channels, along with an internal pipeline. The internal programmes include GCPR targeting drugs for indications in immuno-oncology, neurology and pain.
Icosagen鈥檚 therapeutic pipeline includes multiple candidates for the treatment of neuropathic pain and compounds aimed at cancer cell metabolism.
